Finally, a successful adjuvant therapy for high-risk melanoma
CM Balch and AC Buzaid
JCO Jan 1 1996: 1–3. [PDF]
Selecting treatment for children with acute lymphoblastic leukemia
D Pinkel
JCO Jan 1 1996: 4–6. [PDF]
	Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684
	JM Kirkwood, MH Strawderman, MS Ernstoff, TJ Smith, EC Borden, and RH Blum
	JCO Jan 1 1996: 7–17. [Abstract] [PDF]
	Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
	M Smith, D Arthur, B Camitta, AJ Carroll, W Crist, P Gaynon, R Gelber, N Heerema, EL Korn, M Link, S Murphy, CH Pui, J Pullen, G Reamon, SE Sallan, H Sather, J Shuster, R Simon, M Trigg, D Tubergen, F Uckun, and R Ungerleider
	JCO Jan 1 1996: 18–24. [Abstract] [PDF]
	Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas
	V Combaret, N Gross, C Lasset, D Frappaz, G Peruisseau, T Philip, D Beck, and MC Favrot
	JCO Jan 1 1996: 25–34. [Abstract] [PDF]
	Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group
	RC Coombes, JM Bliss, J Wils, F Morvan, M Espie, D Amadori, P Gambrosier, M Richards, M Aapro, A Villar-Grimalt, C McArdle, FR Perez-Lopez, P Vassilopoulos, EP Ferreira, CE Chilvers, G Coombes, EM Woods, and M Marty
	JCO Jan 1 1996: 35–45. [Abstract] [PDF]
	Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study
	SE Rivkin, S Green, J O'Sullivan, AB Cruz, MD Abeloff, WR Jewell, JJ Costanzi, WB Farrar, and CK Osborne
	JCO Jan 1 1996: 46–51. [Abstract] [PDF]
	Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse
	BG Haffty, M Reiss, M Beinfield, D Fischer, B Ward, and C McKhann
	JCO Jan 1 1996: 52–57. [Abstract] [PDF]
	Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer
	CA Hudis, AD Seidman, JP Crown, C Balmaceda, R Freilich, TA Gilewski, TB Hakes, V Currie, DE Lebwohl, J Baselga, G Raptis, M Gollub, M Robles, R Bruno, and L Norton
	JCO Jan 1 1996: 58–65. [Abstract] [PDF]
	Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes
	M Crump, PE Goss, M Prince, and C Girouard
	JCO Jan 1 1996: 66–69. [Abstract] [PDF]
	Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast
	BE Hillner, CE Desch, RW Carlson, TJ Smith, L Esserman, and HD Bear
	JCO Jan 1 1996: 70–77. [Abstract] [PDF]
	Effect of tamoxifen on bone mineral density measured by dual-energy x- ray absorptiometry in healthy premenopausal and postmenopausal women
	TJ Powles, T Hickish, JA Kanis, A Tidy, and S Ashley
	JCO Jan 1 1996: 78–84. [Abstract] [PDF]
	Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas
	SM Pupa, R Bufalino, AM Invernizzi, S Andreola, F Rilke, L Lombardi, MI Colnaghi, and S Menard
	JCO Jan 1 1996: 85–94. [Abstract] [PDF]
	Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients
	AW Tolcher, KH Cowan, MH Noone, AM Denicoff, DR Kohler, BR Goldspiel, CS Barnes, M McCabe, MR Gossard, J Zujewski, and JA O'Shaughnessy
	JCO Jan 1 1996: 95–102. [Abstract] [PDF]
	Graphs to estimate an individualized risk of breast cancer
	J Benichou, MH Gail, and JJ Mulvihill
	JCO Jan 1 1996: 103–110. [Abstract] [PDF]
	Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma
	JM Duk, KH Groenier, HW de Bruijn, H Hollema, KA ten Hoor, AG van der Zee, and JG Aalders
	JCO Jan 1 1996: 111–118. [Abstract] [PDF]
	Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802
	W Tester, R Caplan, J Heaney, P Venner, R Whittington, R Byhardt, L True, and W Shipley
	JCO Jan 1 1996: 119–126. [Abstract] [PDF]
	Two schedules of teniposide with or without cisplatin in advanced non- small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
	TA Splinter, T Sahmoud, J Festen, N van Zandwijk, S Sorenson, M Clerico, J Burghouts, B Dautzenberg, GS Kho, A Kirkpatrick, and G Giaccone
	JCO Jan 1 1996: 127–134. [Abstract] [PDF]
	Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study
	KM Rowland, Jr, CL Loprinzi, EG Shaw, AW Maksymiuk, SA Kuross, SH Jung, JW Kugler, LK Tschetter, C Ghosh, PL Schaefer, D Owen, JH Washburn, Jr, TA Webb, JA Mailliard, and JR Jett
	JCO Jan 1 1996: 135–141. [Abstract] [PDF]
	Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer
	MJ Millward, JF Bishop, M Friedlander, JA Levi, D Goldstein, IN Olver, JG Smith, GC Toner, D Rischin, and DR Bell
	JCO Jan 1 1996: 142–148. [Abstract] [PDF]
	Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122
	BD Minsky, D Neuberg, DP Kelsen, TM Pisansky, R Ginsberg, and A Benson, 3rd
	JCO Jan 1 1996: 149–155. [Abstract] [PDF]
	Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma
	BA Bates, FC Detterbeck, SA Bernard, BF Qaqish, and JE Tepper
	JCO Jan 1 1996: 156–163. [Abstract] [PDF]
	Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group
	T Conroy, PL Etienne, A Adenis, DJ Wagener, B Paillot, E Francois, L Bedenne, JH Jacob, JF Seitz, H Bleiberg, C Van Pottelsberghe, M Van Glabbeke, FM Delgado, S Merle, and J Wils
	JCO Jan 1 1996: 164–170. [Abstract] [PDF]
	Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases
	S Earlam, C Glover, C Fordy, D Burke, and TG Allen-Mersh
	JCO Jan 1 1996: 171–175. [Abstract] [PDF]
	Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival
	HJ Lenz, CG Leichman, KD Danenberg, PV Danenberg, S Groshen, H Cohen, L Laine, P Crookes, H Silberman, J Baranda, Y Garcia, J Li, and L Leichman
	JCO Jan 1 1996: 176–182. [Abstract] [PDF]
	Geographic variation in patient surveillance after colon cancer surgery
	FE Johnson, LW McKirgan, MA Coplin, AM Vernava, WE Longo, TP Wade, and KS Virgo
	JCO Jan 1 1996: 183–187. [Abstract] [PDF]
	Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies
	RA Larson, R Mick, RT Spielberger, SM O'Brien, and MJ Ratain
	JCO Jan 1 1996: 188–195. [Abstract] [PDF]
	Significance of cytogenetic clonal evolution in chronic myelogenous leukemia
	A Majlis, TL Smith, M Talpaz, S O'Brien, MB Rios, and HM Kantarjian
	JCO Jan 1 1996: 196–203. [Abstract] [PDF]
	Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group
	T Kobayashi, S Miyawaki, M Tanimoto, K Kuriyama, H Murakami, M Yoshida, S Minami, K Minato, K Tsubaki, E Ohmoto, H Oh, I Jinnai, H Sakamaki, A Hiraoka, A Kanamaru, I Takahashi, K Saito, T Naoe, O Yamada, N Asou, S Kageyama, N Emi, A Matsuoka, M Tomonaga, and R Ohno
	JCO Jan 1 1996: 204–213. [Abstract] [PDF]
	Outcome of high-dose therapy and autologous transplantation in non- Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest
	JG Sharp, A Kessinger, S Mann, DA Crouse, JO Armitage, P Bierman, and DD Weisenburger
	JCO Jan 1 1996: 214–219. [Abstract] [PDF]
	Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors
	JE Anderson, FR Appelbaum, G Schoch, T Gooley, C Anasetti, WI Bensinger, E Bryant, CD Buckner, T Chauncey, and RA Clift
	JCO Jan 1 1996: 220–226. [Abstract] [PDF]
	CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial
	MA Fridrik, H Hausmaninger, W Linkesch, M Stoger, H Sill, M Neubauer, HL Seewann, J Klocker, R Haidinger, L Schiller, J Pont, G Raudaschl, M Falk, and T Radaszkiewicz
	JCO Jan 1 1996: 227–232. [Abstract] [PDF]
	Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma
	AH Sarris, A Younes, P McLaughlin, D Moore, F Hagemeister, F Swan, MA Rodriguez, J Romaguera, L North, P Mansfield, D Callendar, O Mesina, and F Cabanillas
	JCO Jan 1 1996: 233–239. [Abstract] [PDF]
	Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte
	M Divine, E Lepage, J Briere, P Pautier, B Dupriez, P Lederlin, P Mineur, H Tilly, M Blanc, B Audhuy, R Herbrecht, B Coiffier, and F Reyes
	JCO Jan 1 1996: 240–248. [Abstract] [PDF]
	Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer
	PJ O'Dwyer, TC Hamilton, FP LaCreta, JM Gallo, D Kilpatrick, T Halbherr, J Brennan, MA Bookman, J Hoffman, RC Young, RL Comis, and RF Ozols
	JCO Jan 1 1996: 249–256. [Abstract] [PDF]
	Predicting etoposide toxicity: relationship to organ function and protein binding
	SP Joel, R Shah, PI Clark, and ML Slevin
	JCO Jan 1 1996: 257–267. [Abstract] [PDF]
	Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy
	M Pecherstorfer, Z Herrmann, JJ Body, C Manegold, M Degardin, MR Clemens, B Thurlimann, M Tubiana-Hulin, EU Steinhauer, M van Eijkeren, HJ Huss, and D Thiebaud
	JCO Jan 1 1996: 268–276. [Abstract] [PDF]
	Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells
	JN Winter, HM Lazarus, A Rademaker, M Villa, C Mangan, M Tallman, L Jahnke, L Gordon, S Newman, K Byrd, BW Cooper, N Horvath, E Crum, EA Stadtmauer, E Conklin, A Bauman, J Martin, C Goolsby, SL Gerson, J Bender, and M O'Gorman
	JCO Jan 1 1996: 277–286. [Abstract] [PDF]
	Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center
	TL Smith, JJ Lee, HM Kantarjian, SS Legha, and MN Raber
	JCO Jan 1 1996: 287–295. [Abstract] [PDF]
	New statistical strategy for monitoring safety and efficacy in single- arm clinical trials
	PF Thall, RM Simon, and EH Estey
	JCO Jan 1 1996: 296–303. [Abstract] [PDF]
	Role of interstitial radiotherapy in the management of clinically organ- confined prostate cancer: the jury is still out
	AV D'Amico and CN Coleman
	JCO Jan 1 1996: 304–315. [Abstract] [PDF]
Physician-drug company conflict of interest
WB Patterson and EJ Emanuel
JCO Jan 1 1996: 316–320. [PDF]
Changing the behavior of breast cancer
G Lawrence
JCO Jan 1 1996: 321–322. [PDF]
Schedule-dependent edatrexate toxicity
EA Perez
JCO Jan 1 1996: 322–323. [PDF]
Treatment of rhabdomyosarcoma
BM Camitta
JCO Jan 1 1996: 323. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.